Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction
Audrey H. Wu,Keith D. Aaronson,Steven F. Bolling,Francis D. Pagani,Kathy Welch,Todd M. Koelling +5 more
Reads0
Chats0
TLDR
There is no clearly demonstrable mortality benefit conferred by MVA for significant MR with severe LV dysfunction, and a prospective randomized control trial is warranted for further study of mortality with MVA in this population.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2005-02-01 and is currently open access. It has received 637 citations till now. The article focuses on the topics: Mitral valve annuloplasty & Mitral regurgitation.read more
Citations
More filters
Book ChapterDOI
Evolution of the Edge-to-Edge Repair: From a Surgical to a Percutaneous Approach
TL;DR: A critical review of the surgical as well as the percutaneous repair data will elucidate the clinical role and the potential for future developments of the edge-to-edge repair in the treatment of mitral regurgitation.
Book ChapterDOI
Mitral Valve Repair
TL;DR: Despite improvements with medical management, 1 year, 3 year and 5-year survival after hospitalization from CHF have been reported at approximately 80–60 %, 50 % and 40–20 % respectively, which is worse than that of most cancers.
Transcatheter Mitral Valve Replacement: Structural and Hemodynamic Analysis
TL;DR: In this article , a transcatheter mitral valve replacement (TMVR) is developed to become a substitute therapy for surgery in prohibitive or high surgical risk patients to treat severe mitral regurgitation.
Book ChapterDOI
Tailored Approach to Functional Mitral Regurgitation
Martin Penicka,Frank Van Praet +1 more
TL;DR: This chapter reviews current causal therapeutic approaches to treat functional MR with focus on an individually tailored strategy to treat moderate to severe MR.
References
More filters
Journal ArticleDOI
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Arthur J. Moss,Wojciech Zareba,W. Jackson Hall,Helmut U. Klein,David J. Wilber,David S. Cannom,James P. Daubert,Steven L. Higgins,Mary W. Brown,Mark L. Andrews +9 more
TL;DR: In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy.
Journal ArticleDOI
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Michael R. Bristow,Leslie A. Saxon,John P. Boehmer,Steven K. Krueger,David A. Kass,Teresa De Marco,Peter E. Carson,Lorenzo DiCarlo,David L. DeMets,Bill G. White,Dale W DeVries,Arthur M. Feldman +11 more
TL;DR: In this paper, the authors tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays.
Journal ArticleDOI
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more